Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.

3 Reasons Why Biohaven Pharmaceuticals' Stock Is Taking Off

NEW HAVEN, Conn., May 18, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted abstracts demonstrating the efficacy, safety, tolerability, and pharmacoeconomic value of NURTEC (rimegepant) on the 2020...

Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform

Biohaven Pharmaceutical Offers Good Value With Nurtec ODT Now On The Market

Atara Biotherapeutics

CymaBay Therapeutics

Marinus Pharmaceuticals

PTC Therapeutics

Solid Biosciences

Telesis Bio Inc

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

7 Disruptive Biotech Stocks to Buy for 2025

The drug enters a crowded market -- but it has a convenient format.

FDA Approves Biohaven's Migraine Treatment Nurtec ODT

Meta-Analysis Suggested That Biohaven Pharmaceutical's Migraine Prevention Trial Is Highly Likely To Succeed

Biohaven’s shares dropped after a failed clinical trial, and risk-tolerant investors are snapping them up.

Should Investors Buy Biohaven's Stock Now?

The company's candidate troriluzole failed to meet its primary endpoint in a trial as a treatment for generalized anxiety disorder.

Biohaven Stock Slides More Than 8% on Drug Trial Failure

Shares of Biohaven Pharmaceutical tumbled Monday after its drug, troriluzole, failed to pass muster as an anxiety medicine. The biotech is still testing troriluzole in three other diseases.

Biotech Stock Crumbles After Drug Fails To Pass Muster In Anxiety

Shares of Biohaven Pharmaceutical Holding Company Ltd. BHVN, -5.18% tumbled 16% in premarket trading on Monday after the company said its experimental treatment for generalized anxiety disorder failed in a clinical trial.

Biohaven's investigational anxiety drug fails in trial

Aimmune Therapeutics

Of the ten most anticipated drug launches expected this year, two will have the biggest impact on the top line—and possibly the share price--of the companies introducing them.

Analysts Forecast Huge Upsides for Aimmune, Biohaven

Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Biohaven (BHVN) Stock

Biohaven has a cash position that should provide enough operating cash to see it through the approval of its two most advanced candidates.

Biohaven: Small Biotech With 2 NDAs Pending FDA Decisions In Early 2020

Allergan

Alector Inc

Amarin Corporation Plc

Athenex

Cara Therapeutics

Global Blood Therapeutics

Intra-Cellular Therapies

Novartis

Puma Biotechnology

Protagonist Therapeutics

Proteostasis Therapeutics

Rocket Pharma

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Biotech’s Year-End To-Do List

Shares of Biohaven Pharmaceutical jumped Friday after the biotech company said it will continue a pivotal study of its Alzheimer's treatment.

This Biotech Says Its Alzheimer's Drug Isn't Futile — And Shares Pop

Late-stage clinical trial results provide a chance for investors to gain significant upside from this developer of drugs combating neurological diseases.

Save Yourself the Migraine and Buy This 1 Pharma Stock Now

Vertex Pharmaceuticals

Allakos Inc

Amicus Therapeutics

Jazz Pharmaceuticals

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses

Today, we take an in-depth look at Biohaven Pharmaceutical, a CNS concern with multiple 'shots on goal'.

Biohaven Pharmaceutical: An Intriguing CNS Play

Biohaven Pharmaceutical (BHVN)'s plans for a secondary offering of $300 million has given both shareholders and speculators a headache.

Biohaven Offering Seems to Make Sale Less Likely

Acer Therapeutics

Celgene

Karyopharm Therapeutics

Merck

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday.

Attention Biotech Investors: Mark Your Calendar For These July 2019 PDUFA Dates

Carnival

Liberty Latin America Ltd.

Liberty Latin America

Odonate Therapeutics

TG Therapeutics

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Weekly CEO Buys Highlight (June 30)

CEO of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Vlad Coric bought 5,000 shares of BHVN on 06/26/2019 at an average price of $40.22 a share.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Bought $201,100 of Shares

Blue Apron

GCP Applied Technologies

These stocks missed out on a big Wall Street rally.

Why Blue Apron Holdings, Biohaven Pharmaceutical Holding, and GCP Applied Technologies Slumped Today

Dilution is coming for shareholders, while an acquisition doesn't seem as likely.

Here's Why Biohaven Pharmaceutical Plummeted Today

News for Biohaven Pharmaceutical Hld Stock (BHVN)